Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gut response. Therapy with ingested immunomodulatory proteins

S A Brod1

  • 1Department of Neurology, University of Texas Health Science Center at Houston, USA.

Archives of Neurology
|October 28, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variable results after rituximab in neuromyelitis optica.

Journal of the neurological sciences·2012
Same author

Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research·2002
Same author

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

Neurology·2001
Same author

Unregulated inflammation shortens human functional longevity.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2000
Same author

Ingested interferon-alpha prevents allograft islet transplant rejection.

Transplantation·2000
Same author

Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2000

Oral myelin therapy for multiple sclerosis (MS) failed in a phase III trial. This highlights challenges in translating animal model findings to human clinical practice for oral tolerization therapies.

Area of Science:

  • Neuroimmunology
  • Clinical Trials
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Oral tolerization, inducing hyporesponsiveness to autoantigens, shows promise in animal models of MS.
  • Developing effective immunomodulatory treatments for MS remains a critical challenge.

Purpose of the Study:

  • To evaluate the efficacy of orally administered bovine myelin (Myloral) in a phase III trial for multiple sclerosis.
  • To assess the clinical translatability of oral tolerization strategies for MS.
  • To explore the potential of the oral route for delivering immunomodulatory proteins.

Main Methods:

  • A 2-year, phase III clinical trial involving patients with multiple sclerosis.

Related Experiment Videos

  • Administration of enteral myelin (Myloral), a bovine myelin preparation, via oral route.
  • Monitoring of treatment efficacy and safety parameters throughout the trial.

    • Main Results:

    • The phase III trial yielded negative results regarding the efficacy of oral myelin therapy.
    • The study suggests that the success of oral tolerization in animal models may not directly translate to clinical efficacy in MS patients.
    • Despite the negative outcome, the oral route remains an area of interest for immunomodulation.

    Conclusions:

    • The oral administration of bovine myelin (Myloral) did not demonstrate efficacy in the phase III trial for multiple sclerosis.
    • Translating the principles of oral tolerization from animal studies to human clinical practice for MS presents significant hurdles.
    • Further research into the oral route for delivering immunomodulatory proteins in MS is warranted, despite trial setbacks.